Bergamo Lymphoid Cancer Registry

Recruiting

• Conditions: Hodgkin Lymphoma; Myeloma; Non Hodgkin Lymphoma
• Interventions: Other: Patient registry

• Registration Number: NCT03131531
• Lead Sponsor: A.O. Ospedale Papa Giovanni XXIII

Brief Summary

This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer

Detailed Description

Lymphoid cancer including Hodgkin disease, non-Hodgkin lymphomas (NHL) and myeloma, represents the most common hematologic malignancy. Despite the overall prognosis improved in the last 10 years, there are many open issues that need to be addressed, specifically refractoriness to standard treatment, disease recurrence and outcome with new drug in the so called "real world" setting. Since the Hematology and Bone Marrow Transplant Unit at "Ospedale Papa Giovanni XIII" of Bergamo has developed specific tools to collect clinical data thought fully validated electronic charts and biological specimens thanks to a regulatory compliant biobanking program, the aim of this study is to collect clinical and biological information of lymphoid cancer patients. The cohort of patients enrolled will permit to analyze the practice pattern, perform biological correlative studies of great translational potential with relevance to clinical practice.

Study Timeline

• Study Start: 2017-03-23
• Study First Submitted: 2017-04-20
• Study First Submitted QC: 2017-04-24
• Study First Posted: 2017-04-27
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-05
• Last Update Posted: 2024-03-06
• Primary Completion: 2027-03-23
• Study Completion: 2037-03-23

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 6000

Inclusion Criteria

• Male or female patients 18 years or older
• Written informed consent
• Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma

Exclusion Criteria

• Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Hodgkin lymphoma	Patient registry	-
Non-Hodgkin lymphoma	Patient registry	-
Myeloma	Patient registry	-

Primary Outcome Measures

Name	Time	Method
Overall survival	20 years	Analyzed for all patients as time from diagnosis to death as a result of any cause, stratified according to intervention and baseline characteristics

Secondary Outcome Measures

Name	Time	Method
Progression-free survival	20 years	Analyzed for all patients, as time from diagnosis to progression of disease or death as a result of any cause, stratified according to intervention and baseline characteristics
Biological correlative studies	20 years	Association between clinical and biologic characteristics
Disease-free survival	20 years	Analyzed only for patients in complete response, as time from achievement of the complete response to relapse or death due to disease or acute toxicity of treatment, stratified according to intervention and baseline characteristics

Trial Locations

Locations (1)

Hematology and Bone Marrow Transplant Unit, A.O. Ospedale Papa Giovanni XXIII; 🇮🇹 Bergamo, Italy